학술논문
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
Document Type
article
Author
Nerina Denaro; Lisa Licitra; Marco Merlano; Francesco Perri; Paolo Bossi; Cristina Gurizzan; Federica Perrone; Athanassios Argiris; Loris De Cecco; Stefano Cavalieri; Mara Serena Serafini; Federico Pistore; Deborah Lenoci; Silvana Canevari; Mario Airoldi; Maria Cossu Rocca; Primoz Strojan; Cvetka Grasic Kuhar; Andrea Vingiani; Maria Grazia Ghi; Alessandra Cassano; Giacomo Allegrini
Source
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Subject
Language
English
ISSN
2051-1426
Abstract
Background Immune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit in clinical trials is variable and heterogeneous. Our study aims at exploring and comparing the predictive role of gene-expression signatures with classical biomarkers for immunotherapy-treated R/M HNSCC patients in a multicentric phase IIIb trial.Methods Clinical data were prospectively collected in Nivactor tiral (single-arm, open-label, multicenter, phase IIIb clinical trial in platinum-refractory HNSCC treated with nivolumab). Findings were validated in an external independent cohort of immune-treated HNSCC patients, divided in long-term and short-term survivors (overall survival >18 and